G uidelines for preventing and treating atherosclerotic disease are heavily focused on low-density lipoprotein (LDL) cholesterol because of strong clinical trial evidence and readily-available plasma measurements.
G uidelines for preventing and treating atherosclerotic disease are heavily focused on low-density lipoprotein (LDL) cholesterol because of strong clinical trial evidence and readily-available plasma measurements. 1 Atherosclerosis originates from cholesterol deposition in the artery from β-lipoproteins, including LDL. However, circulating LDL is a small contributor to total body cholesterol, comprising ≈3 g in a person with circulating LDL cholesterol concentration of 100 mg/dL compared with ≈72 g of total body cholesterol. [2] [3] [4] [5] [6] Moreover, LDL cholesterol is a static measurement that contains no kinetic information about rates of cholesterol production or excretion.
The reverse transport of cholesterol is a multistep pathway beginning with cholesterol extraction from peripheral tissues and macrophages, followed by transfer into a rapidly mixing body cholesterol pool, secretion into the intestine, and excretion in the stool. 7 Reverse cholesterol transport (RCT) may mitigate the effect of LDL cholesterol by removing cholesterol deposited in the arterial wall. This work focuses on the distal portion of RCT, emphasizing the rapidly mixing body cholesterol pool and the intestine. Using multiple stable isotopic tracers to label both dietary and endogenous cholesterol and using a metabolic kitchen diet to provide a constant baseline for measurement, it is possible to quantify total fecal cholesterol excretion and to characterize it as originating from the endogenous pool, the diet, or unlabeled hepatobiliary components. 8 The final common pathway for RCT is the fecal excretion of endogenous cholesterol (FEEC). That measurement, along with related cholesterol fluxes, forms the basis for this report. We define endogenous cholesterol as body cholesterol derived principally from biosynthesis and, to a lesser extent, from absorbed dietary cholesterol. The endogenous cholesterol was labeled by the intravenous administration of cholesterol-d 7 tracer.
Although little evidence exists on the relationship between FEEC and cardiovascular disease (CVD) risk, epidemiological studies have examined plasma biomarkers for the related processes of cholesterol absorption and synthesis, but the results have been inconsistent. 9, 10 Case-control studies also have been controversial, in part because the proposed biomarkers are not fully understood and have not been validated. [11] [12] [13] [14] [15] [16] Actual measurements of whole-body cholesterol metabolism, rather than its biomarkers, are needed to establish a possible relationship between whole-body cholesterol metabolism and CVD.
Increased carotid intima-media thickness (CIMT) has been associated with increased risk of cardiovascular events, such as myocardial infarction and stroke. [17] [18] [19] [20] The Atherosclerosis Risk in Communities study showed a strong relationship between CIMT and cardiovascular events. 20 More recently, a study of the Framingham Offspring Study cohort showed that both the maximum internal CIMT and mean common CIMT predict cardiovascular outcomes. 21 Thus, CIMT is a well-accepted imaging biomarker of atherosclerosis and CVD risk. In the present observational study, we explored whether FEEC was related to CIMT in adults.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Subjects
Among the 100 subjects screened, 94 were eligible and entered the study, and 86 completed the protocol. Subjects included 52 women and 34 men with mean age of 53.7±13.0 years. Table 1 shows the subject characteristics on entry into the study. They comprised a wide range of nondiabetic individuals. Subjects over age 30 years were selected to increase the strength of the relationship of CVD risk factors to CIMT. Statin drug use was allowed because this is a common medication and does not seem to influence whole-body cholesterol metabolism significantly.
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CIMT and Traditional CVD Risk Factors
Pearson correlations between CIMT and several traditional CVD risk factors are shown in Table 2 . Age, systolic blood pressure, hemoglobin A1c, and fasting plasma glucose were associated with increased CIMT, as expected. However, there was no significant relationship between circulating lipids or lipoproteins and CIMT in this sample.
Cholesterol Metabolism
Cholesterol metabolism results are shown in Table 3 . Total daily fecal cholesterol excretion measured was 0.58 g/d. Of this amount, 68% was accounted for by recovery of the plasma tracer cholesterol-d 7 lipoproteins and a portion of tissue cholesterol, averaged 25.3 g. Because the calculated plasma pool of cholesterol was only ≈5.4 g, the rapidly mixing cholesterol pool was comprised 79% tissue cholesterol that equilibrated rapidly with plasma. Percent cholesterol excretion, the percent of the rapidly mixing plasma cholesterol pool excreted daily into the stool as cholesterol and bacterial cholesterol metabolites, was 1.64%. These measurements emphasize that endogenous tissue cholesterol dominates whole-body cholesterol metabolism. Table 3 shows that CIMT was strongly and negatively correlated with several measures of fecal cholesterol elimination, including total cholesterol excretion (P<0.0001), endogenous cholesterol excretion (P<0.0001), unabsorbed dietary cholesterol excretion (P=0.019), and percent cholesterol excretion (P=0.0012). Figure 1 shows a scatterplot of the relationship between CIMT and FEEC. There was no relationship of CIMT to the small amount of unlabeled stool cholesterol, suggesting that unrecognized cholesterol pools do not contribute significantly to CIMT. Percent cholesterol absorption, an important determinant of fecal cholesterol excretion, was positively correlated with CIMT (P=0.0092). Secretion of endogenous cholesterol into the intestine, another determinant of fecal cholesterol excretion, was negatively correlated with CIMT (P=0.011). Although turnover of plasma cholesterol was not measured in the study, it was estimated by the decline in plasma cholesterol enrichment for 13 days after infusion of intravenous tracer. This measurement was positively correlated with CIMT (P=0.0083).
CIMT and Whole-Body Cholesterol Metabolism
Potential Plasma Biomarkers for FEEC
Noncholesterol sterols were measured in plasma to assess their potential use as biomarkers for FEEC in larger studies.
FEEC was positively correlated with the ratio of plasma lathosterol/cholesterol (r=0.283; P=0.0083) and marginally negatively correlated with the ratio of plasma 5α-cholestanol/ cholesterol (r=−0.211; P=0.051). The ratio of 5α-cholestanol/ lathosterol, reflecting the balance of cholesterol absorption to cholesterol biosynthesis, was significantly correlated with FEEC (r=−0.373; P=0.0004). 
Regression Model
Discussion
This work shows that FEEC, the principal pathway of cholesterol elimination in humans, is negatively correlated with CIMT. The data provide a link between whole-body cholesterol metabolism and CIMT, a measure of early atherosclerosis. The association is strong and similar to that of traditional risk factors, such as age, systolic blood pressure, Pearson correlations between factors related to fecal cholesterol excretion and CIMT in 86 subjects. Fecal excretion of total cholesterol includes bacterial degradation products and is also known as fecal neutral sterols. Percent cholesterol excretion is the percent of the rapidly mixing cholesterol pool excreted in the stool per day. Endogenous cholesterol production rate is the sum of fecal cholesterol and bile acid excretion minus unabsorbed dietary cholesterol. Plasma cholesterol-d 7 enrichment change is the decline in plasma cholesterol enrichment from days 2 to 15 expressed as a positive percent of the day 2 value; it is related primarily to the rate of dilution of plasma cholesterol by unlabeled endogenous cholesterol. CIMT indicates carotid intima-media thickness.
and hemoglobin A1c in a study group consisting of 86 relatively healthy nondiabetic subjects between the ages of 30 and 80 years. Moreover, FEEC seems to be a stronger risk factor than HDL and LDL cholesterol, which were not related to CIMT in this small study.
The cholesterol production rate (1.0 g/d) in the present study was similar to previous reports of 1.1 g/day 22 and 1.14 g/d. 23 The rapidly mixing cholesterol pool of 25.3 g in the current study also was similar to the reported pool sizes of 23.4 22 and 25.9 g. 23 The cholesterol flux from the rapidly mixing cholesterol pool out of the body (production rate over the size of the rapidly mixing pool; 4.0%) in the present study was comparable to previous reported values of 4.7% 22 and 4.4%. 23 Others have reported a higher production rate (2.1 g/d) 24 and a lower rapid pool size (11.7 g), 25 probably because of differences in tracer and methods used.
The primary objective in this work was to quantify fecal cholesterol excretion and precisely determine its origins. The analytical methods also allowed us to correlate several secondary end points with CIMT. The complete results form a coherent model for how body cholesterol metabolism might influence CIMT and CVD risk. Figure 2 depicts a working model of cholesterol compartments (circles) and cholesterol fluxes (arrows). The rapidly mixing body cholesterol pool includes all of the cholesterol in liver and blood, as well as part of the cholesterol in other tissues. The rapid cholesterol pool is particularly important because it is the pool from which cholesterol is excreted from the body and into which cholesterol is absorbed. The size of the rapidly mixing cholesterol pool was not directly related to CIMT, but cholesterol fluxes into and out of the pool were significantly correlated with CIMT, either negatively (solid arrows) or positively (dashed arrows). Cholesterol transport processes tending to increase the rapidly mixing pool, such as inflow from unlabeled endogenous cholesterol and reabsorption of intestinal cholesterol, were positively correlated with CIMT, whereas processes tending to reduce the pool size, such as secretion of endogenous cholesterol into the intestine and elimination of cholesterol in the stool, were negatively correlated. Fecal bile acids were not correlated to CIMT and were not included in the model. The results suggest that cholesterol homeostasis is maintained by competing cholesterol transport processes and that individuals who have greater cholesterol excretion have more favorable CIMT values.
LDL and HDL cholesterol have great use in assessing CVD risk, but the information obtained is limited to a static measurement, obtained at a single point in time. HDL cholesterol concentration does not provide information about the quantity of cholesterol flowing into and out of the HDL particles. Previous investigators also found that whole-body cholesterol turnover studied with an intravenous cholesterol tracer was not related to circulating HDL or LDL cholesterol, 26 which may be because of the fact that RCT is the combined actions of various lipoproteins, such as HDL and LDL. More attention has been given to functional assays for HDL. For example, cholesterol efflux capacity of HDL, a functional measure of cholesterol efflux from macrophages, has been shown to relate to atherosclerosis better than HDL cholesterol alone. 27 What distinguishes many cholesterol metabolic parameters in the current study is that they are kinetic and represent cholesterol flows over time. It is possible that kinetic measurements may supplement lipoprotein concentration measurements to provide a stronger prediction of CVD risk.
RCT is an important emerging pathway in which cholesterol efflux from macrophages and peripheral tissues is traced into HDL, through the plasma, and into the intestine, where it is excreted as neutral sterols and bile acids. 7, 28 Although attention has been focused on the arterial macrophage as a first step, the current work shows that cholesterol flowing from all tissues into and out of the rapidly mixing cholesterol pool and intestine may contribute importantly to RCT. In particular, the intestine may have a central role in regulating body cholesterol metabolism and possibly in protecting against the Table 3 . Endogenous cholesterol input into the rapidly mixing pool is estimated as the percent fall in plasma enrichment between days 2 and 15. December 2017 development of atherosclerotic disease. 29 The data presented in Figure 1 show a large interindividual variability in FEEC and support previous work demonstrating similar variability in percent cholesterol absorption. 30 This is likely because of interindividual differences in metabolic regulation rather than analytic error because our previous work shows that repeated FEEC measurements in the same individual have a coefficient of variation of ≈10%.
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Because of the difficulty of performing metabolic tracer studies such as this one, few data exist that address the relationship of whole-body cholesterol metabolism to CVD. It would be highly desirable to have a plasma biomarker for cholesterol excretion. Because cholesterol absorption from the intestine is not complete (averaging 57% in this study), cholesterol homeostasis must be maintained by increased cholesterol synthesis, increased cholesterol absorption, or a combination of these processes to avoid cholesterol deficiency. We used a composite plasma biomarker, the ratio of 5α-cholestanol/lathosterol, to reflect the balance between cholesterol absorption, represented by 5α-cholestanol, and cholesterol biosynthesis, represented by lathosterol, within each individual. The ratio was negatively correlated with FEEC (r=−0.373; P=0.0004) and positively correlated with CIMT (r=0.415; P<0.0001). Previous investigators have shown that similar plasma absorption/synthesis ratios are associated with CVD. 16 It is possible that links to CVD in the absorption/synthesis biomarker literature might be explained, in part, by reduced FEEC as the final common pathway most closely linked to increased CIMT. Conversely, lower intestinal cholesterol absorption would result in cholesterol deficiency and increased compensatory biosynthesis, resulting in a lower absorption/synthesis ratio, higher fecal cholesterol excretion, and lower CVD risk. More work is needed to connect biomarkers with measurements of cholesterol metabolism, transport, CIMT, and CVD outcome.
Although CIMT is not a direct measure of clinical outcomes or events, it does reflect current information on the development of early atherosclerosis, and there is abundant evidence that it is strongly related to well-validated CVD risk factors. The present study demonstrates that FEEC is negatively related to CIMT independently of established CVD risk factors, pointing to FEEC and whole-body cholesterol metabolism as a novel potential target for modulating CVD risk.
It has been demonstrated that bile acid sequestrants effectively reduce coronary artery disease outcomes, probably by reducing LDL cholesterol and increasing sterol excretion or RCT. 31, 32 Failure of CETP (cholesteryl ester transfer protein) inhibitors to reduce cardiovascular events has indicated that it is not sufficient to simply raise HDL cholesterol. 33 The functional capacity of HDL in RCT might be more important mechanistically. Increased fecal cholesterol excretion is a prominent mechanism of action of phytosterols in foods and supplements, 34 but there have been no interventional studies with CVD outcomes to firmly establish the treatment effectiveness. A recent clinical trial of the drug ezetimibe, an inhibitor of cholesterol absorption, resulted in fewer CVD events even in the face of optimum statin drug treatment. 35 Although the result has been attributed to LDL cholesterol lowering, the actual mechanism is unknown, and recent work shows that FEEC is increased ≈70% by ezetimibe. 8 Further work is needed to establish the use of treatments directed toward whole-body cholesterol metabolism.
